alpha-naphthoflavone has been researched along with vorinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartel, K; Bracher, F; Christianson, DW; Herp, D; Jung, M; Marek, M; Müller, M; Ong, N; Porter, NJ; Robaa, D; Romier, C; Schmidtkunz, K; Senger, J; Shaik, TB; Sippl, W; Vögerl, K | 1 |
| Chen, SH; Duan, YC; Guan, YY; He, ZH; Jin, LF; Liu, YJ; Ren, HM; Song, Y; Xu, YT; Yuan, H; Zhang, SJ | 1 |
2 other study(ies) available for alpha-naphthoflavone and vorinostat
| Article | Year |
|---|---|
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Topics: Acetylation; Animals; Catalytic Domain; Cells, Cultured; Crystallography, X-Ray; Histone Deacetylase 6; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; In Vitro Techniques; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Phenothiazines; Structure-Activity Relationship; Zebrafish | 2019 |
Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Deacetylases; Histone Demethylases; Humans; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Rats; Stomach Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |